contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


curasight-lancerer-fortegningsemission-pa-dkk-100-mio

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.

Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Curasight

Curasight: Lancerer fortegningsemission på DKK 100 mio.

Curasight A/S er i front med en banebrydende teknologi til kr&#xe6;ftdiagnostik og -behandling &#x2013; baseret p&#xe5; en innovativ Theranostic-platform, der kombinerer billeddiagnostik (uTRACE&#xae;) og m&#xe5;lrettet behandling (uTREAT&#xae;).
Den 24. april 2025 godkendte bestyrelsen den forest&#xe5;ende fortegningsemission p&#xe5; DKK 100 mio. f&#xf8;r emissions- og garantiomkostninger.
-&#xa0;De nye aktier kan tegnes til kurs DKK 1,98
-&#xa0;Tegningsperioden l&#xf8;ber fra 2. &#x2013; 16. maj 2025
-&#xa0;Forventet f&#xf8;rste handelsdag p&#xe5; de nye aktier er 6. juni 2025
-&#xa0;Curasight har forpligtende tilsagn fra Curium og Pentwater Capital
If&#xf8;lge bestyrelsen vil nettoprovenuet fra den sikrede fortegningsemission v&#xe6;re tilstr&#xe6;kkeligt til at finansiere selskabets drift frem til udgangen af 2025. Dette d&#xe6;kker f&#xe6;rdigg&#xf8;relsen af uTRACE&#xae; fase II-studiet (prostatakr&#xe6;ft), inklusive toplineresultater, samt uTREAT&#xae; fase I-studiet (hjernekr&#xe6;ft), inklusive forel&#xf8;bige effektdata, og vil samtidig sikre det n&#xf8;dvendige driftskapitalbehov.
L&#xe6;s mere og hent oplysningsdokumentet her:&#xa0;<a href="https://www.curasight.com/investor/rights-issue-2025/" target="_blank" rel="noopener">https://www.curasight.com/investor/rights-issue-2025/</a>
Tilmeld dig til dagens event med CEO Ulrich Krasilnikoff og CSO Andreas Kj&#xe6;r her:&#xa0;<a href="https://www.inderes.dk/videos/curasight-praesentation-af-fortegningsemission" target="_blank" rel="noopener">Dagens event</a>
Tidsplan for fortegningsemissionen: &#xa0;
- &#xa0;30. april 2025: F&#xf8;rste handelsdag uden fortegningsret
-&#xa0; 1. maj 2025: Registreringsdato for fortegningsemisssionen
- &#xa0;30. april &#x2013; 14 maj 2025: Handel med tegningsretter
- &#xa0;2. maj &#x2013; 16 maj 2025: Tegningsperiode
- &#xa0;21. maj 2025: Forventet offentligg&#xf8;relse af resultatet af emissionen 
- &#xa0;23. maj 2025: Afviklingsdag
- &#xa0;6. juni 2025: Forventet f&#xf8;rste handelsdag af nye aktier til handel p&#xe5; Spotlight Stock Market. &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; 
Om Curasight Curasight er et klinisk udviklingsselskab med hoveds&#xe6;de i K&#xf8;benhavn, Danmark. Virksomheden er pioner inden for anvendelsen af en innovativ Theranostic-platform, der kombinerer PET-billeddannelse (uTRACE&#xae;) og radioligandterapi (uTREAT&#xae;), m&#xe5;lrettet uPAR-receptoren (urokinase-type plasminogen aktivator-receptoren). Teknologien har potentiale til markant at forbedre kr&#xe6;ftdiagnostik og samtidig muligg&#xf8;re en mere sk&#xe5;nsom og effektiv behandling p&#xe5; tv&#xe6;rs af flere kr&#xe6;ftformer.
Disclaimer: HC Andersen Capital modtager betaling fra Curasight for en Digital IR-aftale. /Claus Thestrup kl. 9:40 den 02/05-2025.